Hypertension: A Companion to Braunwald's Heart Disease

George L Bakris, MD, is a nephrologist whose specialty is kidney function/disease and hypertension. He has led several large NIH-funded studies resulting in paradigm shifts in blood pressure treatment guidelines for patients with treatable and challenging hypertension. Dr Bakris is Professor of Medicine and Director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago in Chicago, Illinois. Matthew J Sorrentino, MD, a cardiologist whose focus is preventive cardiology, is Professor of Medicine at the Bucksbaum Institute for Clinical Excellence and Vice Chair of Clinical Operations for the Department of Medicine at the University of Chicago. Both Drs Bakris and Sorrentino edited the current edition of Hypertension.

SECTION I: EPIDEMIOLOGY 1. General Population and Global Cardiovascular Risk Prediction 2. Hypertension in Latin/Hispanic Population 3. Hypertension in East Asians and Native Hawaiians 4. Hypertension in South Asians SECTION II: PATHOPHYSIOLOGY 5. Pathogenesis of Hypertension 6. Genetics of Hypertension 7. Inflammation and Immunity in Hypertension SECTION III: DIAGNOSIS AND EVALUATION 8. The Environment and High Blood Pressure 9. Office Blood Pressure Measurement 10. Home Monitoring of Blood Pressure 11. Ambulatory Blood Pressure Monitoring in Clinical Hypertension Management 12. White Coat and Masked Hypertension 13. Renovascular Hypertension and Ischemic Nephropathy 14. Secondary Hypertension: Primary Hyperaldosteronism and Mineralocorticoid Excess States 15. Secondary Hypertension: Pheochromocytoma and Paraganglioma 16. Secondary Hypertension: Sleep Disturbances including Sleep Apnea 17. Hypertension in Children: Diagnosis and Treatment SECTION IV: RISK STRATIFICATION 18. Natural History of Untreated Hypertension 19. Isolated Systolic Hypertension 20. Assessment of Target Organ Damage SECTION V: ANTIHYPERTENSIVE THERAPY 21. Diet and Blood Pressure 22. Diuretics in Hypertension 23. Alpha Blockers and Hypertension 24. Renin Angiotensin Aldosterone System Blockers 25. Calcium Channel Blockers 26. Central Sympathetic Agents and Direct Vasodilators 27. Use of Combination Therapies 28. Devices Therapies 29. Alternative Approaches for Lowering Blood Pressure SECTION VI: HYPERTENSION MANAGEMENT 30. Approach to Difficult to Manage Primary Hypertension 31. Hypertension in Ischemic Heart Disease 32. Heart Failure 33. Hypertension and Chronic Kidney Disease 34. Transplant Hypertension 35. Obesity 36. Cerebrovascular Disease 37. Diabetes Mellitus 38. Dyslipidemia SECTION VII: SPECIAL POPULATIONS AND SPECIAL SITUATIONS 39. Hypertension in Pregnancy 40. Hypertension in Older People 41. Hypertension in African Americans 42. Baroreceptor Dysfunction/Orthostatic Hypotension 43. Resistant Hypertension 44. Hypertension and the Perioperative Period 45. Aorta and Peripheral Arterial Disease in Hypertension 46. Hypertensive Emergencies and Urgencies SECTION VIII: OUTCOME TRIALS 47. Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists' Collaboration SECTION IX: HYPERTENSION TREATMENT IN THE FUTURE 48. Team-Based Care for Hypertension Management 49. Understanding and Improving Medication Adherence SECTION X: GUIDELINES 50. Updated AHA/ACC; ESH/ISH 51. Putting All Guidelines into Perspective